AIM ImmunoTech Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
58.6%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.63next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| DURIPANC Phase 2 Primary Endpoint (CBR) Evaluation | 31 Dec 2026 |
| DURIPANC Phase 2 Topline Results Release | 31 Mar 2027 |
| DURIPANC Phase 2 Secondary Endpoints (OS & PFS) Evaluation | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
DURIPANC Phase 2 Clinical Benefit Rate (CBR) Primary Endpoint Evaluation QuarterlyTarget: Evaluation of stable disease, partial response, or complete response at 24 weeks post-therapy initiation
DURIPANC Phase 2 Secondary Endpoints Evaluation (Overall Survival & Progression-Free Survival) QuarterlyTarget: Evaluation of OS, PFS, and immune profiling once the last subject reaches week 49
Cash and Cash Equivalents Quarterly5.8MTarget: Sufficient capital to fund ongoing clinical operations and Phase 3 trial design
Stockholders' Equity Quarterly2.1MTarget: Maintain positive equity to comply with NYSE American listing standards
Watch Items
- NYSE American Listing ComplianceTrigger: Stockholders' equity falling below required thresholds or stock price remaining under $0.20-$0.40Action: Monitor equity deficiency resolutions, warrant reclassifications, and potential reverse stock splits if necessary.
- Phase 3 Clinical Trial Design and InitiationTrigger: Completion of Phase 2 DURIPANC primary endpoint analysis in December 2026Action: Collaborate with Thermo Fisher Scientific's PPD clinical research business to finalize the Phase 3 study design.
- Ebola Program Development (Ampligen as a Prophylactic/Antiviral)Trigger: Emergence of Bundibugyo Ebola strain outbreaks and public health funding opportunitiesAction: Leverage orphan drug designations in the US and EU to secure government or industry partnerships for human trials.
Research as of 20 Jun 2026